News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Oxford BioMedica PLC Clarifies Trovax® Strategy
October 28, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oxford BioMedica (LSE: OXB), the leading gene therapy company, provides clarification of its strategy for its lead cancer immunotherapy, TroVax.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Funding
Novo Foundation Pumps $850M Into Denmark, Europe to Bolster Innovation
January 16, 2026
·
2 min read
·
Tristan Manalac
Insights
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
January 15, 2026
·
2 min read
·
Jennifer Smith-Parker
Job Trends
3 Top Challenges Facing Manufacturing Professionals Right Now
January 15, 2026
·
6 min read
·
Angela Gabriel
Opinion
Trump Must Make Biotech Innovation a National Priority
January 14, 2026
·
7 min read
·
Cyriac Roeding
